NASDAQ:GLPG Galapagos (GLPG) Stock Price, News & Analysis $25.85 -0.17 (-0.65%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Galapagos Stock (NASDAQ:GLPG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Galapagos alerts:Sign Up Key Stats Today's Range$25.73▼$26.1550-Day Range$22.69▼$28.7952-Week Range$22.36▼$34.02Volume156,626 shsAverage Volume183,512 shsMarket Capitalization$1.70 billionP/E RatioN/ADividend YieldN/APrice Target$26.75Consensus RatingStrong Sell Company OverviewGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Read More… Remove Ads Galapagos Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreGLPG MarketRank™: Galapagos scored higher than 4% of companies evaluated by MarketBeat, and ranked 930th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingStrong Sell Consensus RatingGalapagos has received a consensus rating of Strong Sell. The company's average rating score is 1.44, and is based on no buy ratings, 4 hold ratings, and 5 sell ratings.Amount of Analyst CoverageGalapagos has only been the subject of 3 research reports in the past 90 days.Read more about Galapagos' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Galapagos are expected to decrease in the coming year, from ($1.60) to ($3.11) per share.Price to Book Value per Share RatioGalapagos has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Galapagos' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.54% of the float of Galapagos has been sold short.Short Interest Ratio / Days to CoverGalapagos has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Galapagos has recently increased by 25.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGalapagos does not currently pay a dividend.Dividend GrowthGalapagos does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.54% of the float of Galapagos has been sold short.Short Interest Ratio / Days to CoverGalapagos has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Galapagos has recently increased by 25.43%, indicating that investor sentiment is decreasing significantly. News and Social Media1.5 / 5News Sentiment0.70 News SentimentGalapagos has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Galapagos this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added Galapagos to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Galapagos insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.91% of the stock of Galapagos is held by insiders.Percentage Held by InstitutionsOnly 32.46% of the stock of Galapagos is held by institutions.Read more about Galapagos' insider trading history. Receive GLPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter. Email Address GLPG Stock News HeadlinesMorgan Stanley Sticks to Their Sell Rating for Galapagos (GLPG)March 10, 2025 | markets.businessinsider.comGalapagos NV: Galapagos to Present at Upcoming Investor ConferencesFebruary 24, 2025 | finanznachrichten.deLying in hospital… staring at the light"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.March 18, 2025 | Porter & Company (Ad)Galapagos NV to Present at Major Investor Conferences in MarchFebruary 24, 2025 | tipranks.comGalapagos to Present at Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comGalapagos' Strategic Shift: Betting On CAR-T And A Fresh Start (Rating Upgrade)February 20, 2025 | seekingalpha.comDisount To Net Cash For A Promising CAR-T CompanyFebruary 20, 2025 | seekingalpha.comGalapagos price target lowered to EUR 22 from EUR 28 at Deutsche BankFebruary 20, 2025 | markets.businessinsider.comSee More Headlines GLPG Stock Analysis - Frequently Asked Questions How have GLPG shares performed this year? Galapagos' stock was trading at $27.50 at the start of the year. Since then, GLPG shares have decreased by 5.8% and is now trading at $25.9150. View the best growth stocks for 2025 here. How were Galapagos' earnings last quarter? Galapagos NV (NASDAQ:GLPG) issued its quarterly earnings data on Thursday, February, 21st. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.82. When did Galapagos IPO? Galapagos (GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers. Who are Galapagos' major shareholders? Top institutional investors of Galapagos include Gilead Sciences Inc. (25.35%), Tang Capital Management LLC (3.28%), Deep Track Capital LP (1.18%) and Segall Bryant & Hamill LLC (1.04%). How do I buy shares of Galapagos? Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Galapagos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galapagos investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings2/21/2019Today3/18/2025Next Earnings (Estimated)4/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLPG CIK1421876 Webwww.glpg.com Phone(321) 534-2900Fax321-534-2901Employees1,123Year Founded1999Price Target and Rating Average Stock Price Target$26.75 High Stock Price Target$31.00 Low Stock Price Target$22.00 Potential Upside/Downside+2.8%Consensus RatingStrong Sell Rating Score (0-4)1.44 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio9.97 Quick Ratio9.81 Sales & Book Value Annual Sales$275.65 million Price / Sales6.22 Cash FlowN/A Price / Cash FlowN/A Book Value$47.57 per share Price / Book0.55Miscellaneous Outstanding Shares65,900,000Free Float63,979,000Market Cap$1.71 billion OptionableOptionable Beta0.18 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:GLPG) was last updated on 3/18/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredFormer CIA to Trump – Will you Shut down this secret lab?Deep in the sands of New Mexico lies a government lab so secret it makes Area 51 look like a tourist spot… ...Paradigm Press | SponsoredIs this the End of the AI Boom?If you’re worried about all the recent volatility in the market… Or if you have any money in AI stocks… ...Brownstone Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMusk’s real agenda in D.C. Companies connected to Elon’s new map of America are making major climbs in price. And on May 30, the next wav...Porter & Company | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galapagos NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Galapagos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.